LEO 43204: Clinical Trials

4 completed, 1 terminated. 3 Phase 1, 3 Phase 2, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel - Actinic Keratosis, Squamous Cell Carcinoma	Phase 3	Terminated	LEO Pharma	563	2017-06-16	2025-03-11
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel LEO 43204, LEO 43204 Vehicle - Actinic Keratosis	Phase 1	Completed	LEO Pharma	233	2016-02-01	2025-02-24
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively LEO 43204 - Actinic Keratosis	Phase 2	Completed	LEO Pharma	189	2015-03-01	2025-03-10
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis LEO 43204, Placebo - Actinic Keratosis	Phase 1 / Phase 2	Completed	LEO Pharma	224	2014-05-01	2025-03-06
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis LEO 43204, Placebo - Actinic Keratosis	Phase 1 / Phase 2	Completed	LEO Pharma	220	2014-05-01	2025-03-06

United States (5) · Canada (2) · France (1) · Germany (1) · Spain (1) · United Kingdom (1)

2014 (1), 2017 (1)